The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global facial injectables market size reached US$ 7.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 12.2 Billion by 2027, exhibiting a growth rate (CAGR) of 9.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
facial injectables are administered on specific areas of the face to enhance the physical appearance of the skin. These injectables are generally made using collagen, hyaluronic acid and calcium hydroxylapatite that help restore the elasticity of the skin. They are used to reduce wrinkles, augment lips, enhance shallow contours and raise depressed scars. Currently, facial injectables are gaining traction worldwide as they are safe, cost-effective and require minimal downtime.
As collagen production and formation of fat under the skin decline with age, the skin becomes more susceptible to wrinkles and sagging. This, in confluence with the growing geriatric population and the desire to retain a young and healthy skin, represents one of the key factors bolstering the market growth. Apart from this, the escalating demand for minimally invasive surgeries, coupled with the rising trend of medical and cosmetic tourism, is contributing to the market growth. Moreover, as excessive sun exposure leads to tissue breakdown of the skin, the demand for facial injectables is escalating among outgoing individuals. Furthermore, inflating disposable incomes, the rising influence of social media, and the growing number of professional practitioners and users willing to try organic and biodegradable materials are some of the other factors influencing the market positively. Besides this, the key players are also offering customized facial injectables to provide a personalized experience to users, which, in turn, is anticipated to create a positive outlook for the market in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global facial injectables market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, application type, application and end user.
Breakup by Product Type:
Breakup by Application Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan Plc, Anika Therapeutics Inc., Bloomage BioTechnology, Johnson & Johnson, Galderma Pharma S.A., Integra LifeSciences, Ipsen (Mayroy SA), Medytox Inc., Merz Holding GmbH & Co. KG, Prollenium Medical Technologies Inc., Sanofi, SciVision Biotech Inc., Sinclair Pharma (Huadong Medicine Co. Ltd.), Suneva Medical Inc. and Bausch Health Companies Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Application Type, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Allergan Plc, Anika Therapeutics Inc., Bloomage BioTechnology, Johnson & Johnson, Galderma Pharma S.A., Integra LifeSciences, Ipsen (Mayroy SA), Medytox Inc., Merz Holding GmbH & Co. KG, Prollenium Medical Technologies Inc., Sanofi, SciVision Biotech Inc., Sinclair Pharma (Huadong Medicine Co. Ltd.), Suneva Medical Inc. and Bausch Health Companies Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
According to the estimates by IMARC Group, the global facial injectables market is expected to witness a CAGR of 9.5% from 2022 to 2027.
The expanding cosmetic surgery sector with the rising consumer consciousness towards physical appearances represents one of the key drivers for the global facial injectables market.
The emergence of minimally- or non-invasive cosmetic surgeries along with the increasing demand for organic and biodegradable product variants account for some of the key industry trends in the global facial injectables market.
Sudden outbreak of the COVID-19 pandemic had led to the cancellation or postponement of several elective cosmetic surgeries to mitigate the risk of coronavirus infection upon clinic visits that had adversely impacted the market for facial injectables.
On the basis of the product type, the market has been bifurcated into collagen, Hyaluronic Acid (HA), Botulinum Toxin Type A, Calcium Hydroxylapatite (CaHA), Polymethylmethacrylate Beads (PMMA Microspheres), Poly-L-Lactic acid (PLLA), and others. Currently, Botulinum Toxin Type A holds the majority of the total market share.
Based on the application type, the market has been segmented into aesthetics and therapeutics. Amongst these, aesthetics represent the largest segment.
On the basis of the end user, the market has been bifurcated into hospitals, dermatology clinics, and others. Among these, hospitals hold the largest market share.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
The key companies in the global facial injectables market are Allergan Plc, Anika Therapeutics Inc., Bloomage BioTechnology, Johnson & Johnson, Galderma Pharma S.A., Integra LifeSciences, Ipsen (Mayroy SA), Medytox Inc., Merz Holding GmbH & Co. KG, Prollenium Medical Technologies Inc., Sanofi, SciVision Biotech Inc., Sinclair Pharma (Huadong Medicine Co. Ltd.), Suneva Medical Inc., and Bausch Health Companies Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at